Crossject Société Anonyme (ALCJ.PA)

EUR 1.0

(0.1%)

Market Cap (In EUR)

46.09 Million

Revenue (In EUR)

145 Thousand

Net Income (In EUR)

-8.63 Million

Avg. Volume

212.14 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.52-5.96
PE
-3.57
EPS
-0.28
Beta Value
0.848
ISIN
FR0011716265
CUSIP
F2397U146
CIK
-
Shares
46094538.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Mr. Patrick Alexandre
Employee Count
-
Website
https://www.crossject.com
Ipo Date
2014-02-20
Details
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.